What's Happening?
Several academic and nonprofit health systems have filed lawsuits against CVS Health, alleging that the company and its subsidiaries improperly retained approximately $250 million in savings from the 340B Drug Pricing Program between 2020 and 2025. The
lawsuits, filed in federal courts in New York, Kansas, and Michigan, claim that CVS Health subsidiaries, including CaremarkPCS, Caremark LLC, CVS Specialty, and Wellpartner, conspired to lower the 340B remittance to hospitals, diverting funds intended for safety-net hospitals. The hospitals argue that this practice violates CVS Health's mission to lower healthcare costs and improve access to care for underserved communities.
Why It's Important?
The allegations against CVS Health highlight significant concerns about the management and distribution of funds within the 340B Drug Pricing Program, which is designed to support safety-net providers. If proven, these practices could undermine the program's goal of expanding access to affordable healthcare for vulnerable populations. The lawsuits also raise questions about the role of pharmacy benefit managers and contract pharmacies in the healthcare system, particularly regarding transparency and accountability. The outcome of these legal proceedings could have broader implications for the regulation of the 340B program and the operations of large healthcare corporations.
What's Next?
The hospitals are seeking a court declaration that CVS Health breached its contracts and are demanding a full accounting of the funds allegedly retained. They aim to recover the misappropriated funds to reinvest in expanding access to care for underserved communities. The legal proceedings could prompt increased scrutiny of CVS Health's practices and potentially lead to regulatory changes in the administration of the 340B program. CVS Health has yet to respond to the allegations, and the outcome of the lawsuits could influence future corporate practices and policies regarding healthcare cost management.
